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Indirubins represent a group of natural and synthetic products with bio-activities against numerous 32 
human cancer cell lines acting by inhibiting protein kinases. The natural sources of indirubins are 33 
plants of Isatis sp., Indigofera sp., and Polygonum sp., recombinant bacteria, mammalian urine 34 
and some marine mollusks. Specifically, the halogenated derivative 6-bromo indirubin-3′-oxime 35 
(6BIO) possesses increased selectivity against GSK-3. However, to our knowledge, no analytical 36 
method to determine 6BIO in biological fluids has been developed till now. Therefore, a rapid, 37 
sensitive and high throughput UHPLC-MS/MS methods were developed and validated to evaluate 38 
the concentrations of 6BIO in mice plasma. Plasma samples were pre-treated by protein 39 
precipation using cold mixture of methanol: acetonitrile (9:1, v/v) and separations were carried out 40 
on a Hypersil Gold C18 column (50 × 2.1 mm i.d.; 1.9 µm p.s.) using 0.1% acetic acid and 41 
methanol as mobile phase at a flow rate of 500 mL/min in a gradient mode. For quantitation, a 42 
hybrid LTQ-Orbitrap MS equipped with an electro-spray ionization source was used applying a 43 
selected reaction monitoring (SRM) option. The monitored transitions were m/z 354.0 → 324.0 44 
for 6BIO and 297.1 → 282.1 for afromorsin (used as the internal standard) in the negative mode. 45 
Following the EMA, ICH and FDA guidelines for validation of analytical procedures, the assay 46 
method was fully validated in terms of selectivity, linearity, recovery, matrix effect, accuracy, 47 
precision, stability, and robustness. The validated methods were successfully applied to the 48 
pharmacokinetic studies of 6BIO following an oral administration to mice at the dose of 50 mg/kg. 49 
The results indicated that 6BIO possesses a Tmax of 30 min, a half-life of 1 h, and low plasma 50 
bioavailability. 51 




1. Introduction 54 
Indirubins are bis-indole alkaloid compounds occurring naturally in various indigo-containing 55 
plants such as Isatis spp – Brassicaceae (1, 2), Indigofera spp – Leguminoseae (3), Polygonum spp 56 
– Polygonaceae (4), Strobilanthes spp - (5). Besides their importance in the dye industry history, 57 
these compounds display important biological activities with a particular focus on the inhibition 58 
of protein kinases (6). A secondary natural source of indirubins are mollusk gastropods from 59 
Muricidae family such as Hexaplex trunculus (7), Plicopurpura spp (8), and others (9). Plant 60 
indirubin have been found as the active principle of the anti-leukemial Traditionnal Chinese 61 
Medicine (TCM) Danggui Longgui Wan (10-11), with a particular action against Cyclin-62 
Dependent Kinases (12). On the other hand, the mollusk derived halogenated analogue, 6-bromo 63 
indirubin (6BI) inhibits preferably the mamalian Glycogen Synthase Kinase-3 (GSK-3) (13, 14). 64 
The anti-protein kinase activities of natural occurring indirubins have attracted the attention of the 65 
scientific community this last decade, leading to a particular increase of interest in the study of the 66 
biology and the chemistry of indirubins as reviewed in (15-17). Therefore, hundreds of indirubin 67 
derivatives have been developed during the recent years, aiming towards the investigation and 68 
amelioration of the activity, selectivity and drug-likeness of indirubins (18-22). 69 
6-bromoindirubin-3′-oxime (6BIO) is a semi-synthetic analogue of 6BI that was developed as a 70 
potent and selective GSK-3β inhibitor (23) and is currently considered as a prototype inhibitor of 71 
that mammalian kinase. 6BIO has also been used to maintain pluripotency of mouse and human 72 
embryonic stem cells through the reversible Wnt pathway activation, suggesting therefore its 73 
applications in regenerative medicine (24). Besides GSK3β inhibition, 6BIO also inhibits 74 
JAK/STAT3 signaling, induces apoptosis of melanoma cells in vitro and suppresses tumor growth 75 
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in vivo with low toxicity in a mouse xenograft model of melanoma (25). This anti-cancer like 76 
activity of 6BIO has been also investigated in the metastatic process of cancer cell lines in vitro: 77 
6BIO inhibited adhesion, migration and invasion of a variety of metastatic cell types by inhibiting 78 
several kinase cascades such as PDK1, GSK3β and Jak/STAT3 (26). These results were confirmed 79 
by an in vivo experiment where 6BIO decrease significantly lung metastasis in the well-established 80 
4T1 mouse model of aggressive breast cancer after a treatment at the dose of 1 mg/kg. Another 81 
reported mode of action of 6BIO is its potential to fight TRAIL (TNFα-related apoptosis-inducing 82 
factor) resistant cancer cells (27). Futhermore, 6BIO was recently found to be a full agonist of 83 
AhR, it participates, through AhR signaling, to the induction of Cytochrome P450-1A2 which is 84 
involved in one of the key metabolic functions of the liver (Briolotti et al., 2015). Moreover, the 85 
commercialization of 6BIO by Calbiochem (Merck-Millipore) and Santa Cruz Biotechnology 86 
under the name GSK-3 Inhibitor IX (CAS 667463-62-9) is a clear indication of its value as a tool 87 
for the exploration of physiological pathways. Despite the pleiotropic effects of indirubin 88 
derivatives and 6BIO in particular, scientific reports regarding the determination of 6BIO in 89 
biological fluids are very scarce. 90 
To further explore the potential of 6BIO, a bioanalytical method was needed in view of 91 
pharmacokinetic studies with this compound. We therefore report here the development and 92 
validation of an UHPLC-ESI-HRMS/MS method for the determination of 6BIO in mice plasma. 93 
The use of UHPLC ensured the short analysis time (4.4 min), whereas the hybrid LTQ-Orbitrap 94 
Mass Spectrometer and the application of the SRM option offered high mass measurement 95 
accuracy and exclusion of any possible matrix interference and false positives from endogenous 96 
components having the same nominal mass. Overall, the developed methodology is suitable for 97 
high-throughput analysis requirements in the context of simple and efficient extraction with small 98 
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plasma volume, reduced analysis time and high sensitivity, all being necessary requirements for 99 
accessing the pharmacokinetic profile of the drug. The developed methodology has been used to 100 
access the pharmacokinetic profile of 6BIO after its administration in healthy mice.  101 
2. Material and methods 102 
2.1 Chemicals and reagents 103 
6BIO (Figure 1) was synthesized as previously described (35). Afrormosin (I.S.) was isolated as 104 
previously described (28). Glacial acetic acid and LC-MS grade water were purchased from Merk 105 
(Damstart, Germany). LC-MS grade acetonitrile and methanol were purchased from Carlo Erba 106 
(Val de Reuil, France). 107 
2.2 Ultra-high performance liquid chromatography  108 
The samples were analyzed on a UHPLC-LTQ-Orbitrap Discovery system (Thermo Scientific, 109 
Bremen, Germany) consisted of an Accela UHPLC system coupled to a hybrid LTQ-Orbitrap 110 
Discovery Mass spectrometer. An aliquot of 10 μL of sample was injected onto a C18 Hypersil 111 
GOLD column (50 × 2.1 mm i.d., 1.9 μm particle size, Thermo Scientific) with a flow rate of 500 112 
μL/min at room temperature. The LC linear gradient was increased from 10% B to 55% B in 2 min 113 
(A, water with 0.1% acetic acid; B, acetonitrile), held at 55% B for 0.3 min, and then increased to 114 
100% B in 1 min, restored to 10% in 0.1 min and held at 10% B for 1 min. The total run time was 115 
4.4 min. 116 
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2.3 Mass spectrometry 117 
Mass spectrometric detection was carried out on an LTQ-Orbitrap Discovery Mass Spectrometer 118 
(Thermo Finnigan) with an electrospray ionization (ESI) interface. The ESI source was set in 119 
negative ionization mode. Quantitation was performed using multiple reaction monitoring (MRM) 120 
of the transitions of m/z 354.0 → 324.0 and m/z 297.1 → 282.1 for 6BIO and Afrormosin 121 
respectively (Figure 2). The peak area ratio of 6BIO to the IS was used for the quantification of 122 
6BIO in plasma samples. The optimized ionization parameters were as follows: ion spray voltage 123 
of 3.5 kV, temperature 300 oC, capillary voltage -50 V and tube lens -50 V. Two microscans were 124 
applied with a maximum injection time of 100 ms. Nitrogen was used as sheath gas (flow rate 50 125 
arbitrary units) and auxiliary gas (flow rate of 10 arbitrary units). All samples were analysed in 126 
duplicate and data were acquired and processed using the Xcalibur 2.0 software.  127 
2.4 Standard solutions, calibration standards and quality control 128 
samples 129 
A stock solution of 6BIO was prepared by dissolving 5 mg of crystaline 6BIO in 5 ml of DMSO. 130 
The stock solution of the IS (Afrormosin) was prepared by dissolving 5 mg of the IS in 5 mL of 131 
methanol. Acetonitrile and water were used as solvent in the ratio of 1:1 (v/v) throughout the 132 
analysis. The stock solution of 6BIO was further diluted to give a series of sub-standard solutions 133 
with the concentrations of 50, 100, 250, 500, 1000, 1250, 1500 and 2000 ng/mL. The IS stock 134 
solution (1.0 mg/mL) was further diluted in methanol (HPLC grade) to yield a working standard 135 
solution of 500 ng/mL and subsequently stored at -20 oC pending analysis. The calibration 136 
standards of 6BIO were prepared by spiking 0.45 μL of 9 series of analyte-free mice plasma with 137 
5 μL of the 9 series of appropriate 6BIO working standard solutions leading to plasma with a new 138 
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series of concentrations (5.0, 10, 25, 50, 100, 125, 150 and 200 ng/mL). LLOQ (5 ng/mL) and the 139 
ULOQ (200 ng/mL) were prepared in pentaplicate. Similarly, the quality control (QC) samples 140 
were prepared in pentaplicate using analyte-free mice plasma at concentrations of 7.5, 40 and 175 141 
ng/mL. 142 
2.5 Sample preparation 143 
Protein precipitation was used for the treatment of plasma samples prior to the LC-MS analysis. 144 
25 μL of the IS working solution was added to 225 μL of acetonitrile, vortexed for 30 s and 145 
maintained at -20 oC. This new IS solution of 50 ng/mL (acetonitrile/methanol: 9/1, v/v) was added 146 
to 50 μL of the plasma samples containing the analytes. The resulting suspension vortex-mixed 147 
for 1 min, then centrifuged for 5 min (12000 rpm) and finally 10 μL of the supernatant were 148 
injected into the UHPLC-LTQ-orbitrap system. 149 
2.6 Method validation 150 
The method was validated for selectivity, carry-over, linearity, accuracy, precision, dilution 151 
integrity, robustness, matrix effect, extraction recovery and stability according to the International 152 
Conference on Harmonization (ICH, 2005) Q2 (R1) procedures, the Bioanalytical Method 153 
Validation Draft Guidance of the US Food and Drug Administration (FDA, 2013) and the 154 
Guideline Bioanalytical method validation of the European Medicines Agency (EMA, 2011). The 155 
peak area ratios of 6BIO to the I.S. of QC samples were interpolated from the calibration curve on 156 
the same run to afford the concentration of 6BIO. 157 
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2.6.1 Accuracy and precision  158 
Precision and accuracy were evaluated by analyzing the samples at the three QC concentration 159 
levels, along with the LLOQ and ULOQ at five replicates during three validation days. The 160 
concentration of each sample was determined using the calibration curve prepared on the same 161 
day. Precision was expressed using the coefficient of variation (CV, %) between the replicate 162 
measurements. Accuracy was defined as the % relative error, .i.e. relative deviation in the 163 
determined concentration of a standard from that of its nominal concentration expressed as a 164 
percentage. The precision required was CV% within 15%, and accuracy were required not to 165 
exceed ±15%. 166 
 167 
2.6.2 Specificity and selectivity 168 
The interference of endogenous compounds in mice plasma was assessed as follows: Six blank 169 
plasma from six different mice were processed without addition of 6BIO and I.S, and were 170 
quantified using a valid calibration curve in order to test for possible interference at the retention 171 
time of 6BIO and the IS. For all the rat plasma batches, the peak area measured in the blank plasma 172 
sample had not to exceed 20% of the LLOQ peak area for 6BIO, and 5% for IS. 173 
2.6.3 Calibration model, LLOQ and ULOQ  174 
The calibration model curves for 6BIO was assessed by analyzing nine calibration standard 175 
samples in the range of 5.0 – 200 ng/mL in duplicate, employing the peak-area ratio of each analyte 176 
to that of the IS versus its plasma concentration, A quadratic weighted (1/x) least squares regression 177 
approximation has been selected as the most appropriate model. 178 
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The LLOQ was defined as the lowest concentration on the calibration curves of 6BIO measured 179 
with acceptable precision and accuracy (i.e. within ± 20% bias of the nominal value and with a 180 
%CV less than 20%) and a signal to noise ratio of at least 5. The ULOQ was defined as the highest 181 
concentration on the calibration curves of 6BIO. 182 
2.6.4 Recovery (extraction efficiency) 183 
Recovery of 6BIO after protein precipitation was estimated at the three QC concentration levels, 184 
as well as to the LLOQ and ULOQ by comparing the mean peak area ratios of the 6BIO to IS in 185 
pre- spiked extracted samples with post-spiked extracted blank samples, representing 100% 186 
recovery. In each case, five replicates were analyzed. 187 
2.6.5 Matrix effect 188 
The matrix effect was tested by comparing post-spiked blank samples to the corresponding 189 
standard saples at three QC concentration levels, as well as at the LLOQ and ULOQ. In each case, 190 
five replicates were analyzed. A value of 100% is indicative of no matrix effect, a value >100% 191 
suggests ionization enhancement and a value <100% suggests ionization suppression.  192 
2.6.6 Carry over 193 
For the evaluation of carryover effects, two plasma sample at the ULOQ level and two processed 194 
blank plasma were analyzed in consecutive LC-MS/MS runs. For acceptance, the peak areas of 195 




2.6.7 Stability 198 
In order to simulate the experimental conditions that an unknown sample may be exposed during 199 
a routine analysis, free/thaw, autosampler, short term, and long term stabilities of samples were 200 
carried out and always compared to that of a freshly prepared sets of calibrations and QC samples. 201 
At each concentration level, the precision expressed as CV% had not to exceed 15%, and the 202 
accuracy expressed as %Er had to be within ±15% of the nominal value. 203 
2.6.7.1 Three freeze - thaw cycles  204 
Five replicates at the three QC concentration levels, LLOQ and ULOQ were subjected to three 205 
freeze/thaw cycles (from freeze temperature of -20 ºC to room temperature) and were quantified 206 
using the developed methodology.  207 
2.6.7.2 Short term stability  208 
Five replicates at the three QC concentration levels, LLOQ and ULOQ were stored for 6 h at room 209 
temperature before processing and analysis.  210 
2.6.7.3 Autosampler stability  211 
Five replicates at the three QC concentration levels, LLOQ and ULOQ were processed and stored 212 
at in the autosampler at 8 °C and protected from light, for 10 h and then analyzed. 213 
2.6.7.4 Long term stability  214 
Long-term stability of samples was evaluated by analyzing QC, LLOQ and ULOQ samples that 215 
were stored for 20 days at -80 °C.  216 
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2.6.7.5 Robustness  217 
The robustness study was carried out to evaluate the influence of small deliberate variations of the 218 
optimized chromatographic conditions. Three different parameters were altered, within a 5-10% 219 
margin of the value used for the analysis, in order to evaluate the robustness of the proposed 220 
methodology. These parameters were the flow rate, the column temperature and the percentage of 221 
acetic acid in the aqueous phase. Thus, the values studied were 450, 500 and 550 μL/min for the 222 
flow rate, 22, 24 and 26°C for the column temperature and 0.095, 0.1 and 0.105% for the 223 
percentage of acetic acid in the aqueous phase. This study was performed at the LLOQ, ULOQ 224 
and the QCs levels (n = 5). The evaluation of the results was accomplished by ANOVA. 225 
2.7 Pharmacokinetic study 226 
The validated methodology was applied to determine the plasma concentration of 6BIO in mice 227 
(n=3) up to 24h. 6BIO solutionin  aqueous Solutol (30% w/v) was administered to mice at a single 228 
dose of 50 mg/kg body weight (BW) by oral gavage. Blood samples were collected in 229 
microcentrifuge tubes containing EDTA anticoagulants at intervals of 0, 5, 15, 30 min, and 1, 4, 230 
6, 8, 12, and 24 h . Then, blood samples were centrifuged at 1500 rpm for 5 min at room 231 
temperature. The obtained plasma samples were transferred into clean microcentrifuge tubes and 232 
frozen at -80oC.  233 
Mean plasma concentrations of 6BIO after oral administration versus time curve were generated 234 
in Microsoft Excel. The pharmacokinetic (PK) parameters were determined by non-compartmental 235 
analysis of the individual plasma concentration profiles using the PKsolver (add-in program for 236 
Microsoft Excel) The PK parameters determined were the maximum concentration (Cmax), the time 237 
to reach the maximum concentration (Tmax), the terminal elimination half-life (t1/2), the elimination 238 
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rate constant (Ke), the area under the curve from time zero to the last detectable sampling point 239 
after administration (AUC0→ last ) and the area under the curve extrapolated to infinity (AUC0–240 
∞),(calculated with the linear/log trapezoidal method), the mean residence time (MRT), the volume 241 
of distribution at terminal phase (Vz), and the clearance (CL).  242 
3 Results and Discussion  243 
3.1. Optimization of UHPLC-ESI MS/MS conditions 244 
Despite the long history of indirubins in traditional, industrial and clinical practices, reported 245 
methods for their quantitation in biofluids are very scarce. The first analysis of indirubins in rat 246 
plasma was carried out using an HPLC-UV method (29). The limitations of this study were the 247 
use of a low resolution and non-specific detection technique (UV), as well as the lengthy 248 
chromatographic run times (env. 20 min). Hang et al. developed an HPLC-MS/MS method for the 249 
quantitation of mesoindigo – an indirubin isomer – and its reductive metabolites in rat plasma (30), 250 
with total analysis time reaching 30 min, which is a drawback in the analysis of a large number of 251 
samples. Therefore, the main aim of this study was to develop an analytical methodology featuring 252 
short analysis time for the quantitation of 6BIO in rat plasma. The UHPLC separation methodology 253 
was employed due to its inherent capability of affording ultra-high resolution chromatographic 254 
runs in a considerably short analysis time. The selected mobile phase (ACN and H2O containing 255 
0.1% FA) resulted in separation between 6BIO and the IS in 4.4-min run time (Figure 2). This 256 
ultra-fast chromatographic separation of the analytes was combined with MS/MS spectral 257 
detection, thus providing enhanced specificity and sensitivity. The MS/MS spectra from a Linear 258 
Ion Trap based quantitative bioanalysis assay allows not only the separation and differentiation of 259 
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endogenous compounds in biological matrices from the drug compound of interest or its 260 
metabolites, but also the elimination of any questions about false-positive data. 261 
The first step of our method development was to acquire the high resolution Fourier transform full 262 
scan and MS/MS spectra of 6BIO in both positive and negative mode. For this purpose, a 10 μg/mL 263 
solution diluted in MeOH:H2O (1:1, v/v) was directly infused into the MS system at a flow rate of 264 
5 μL min-1. The ESI interface parameters and the ESI probe position were also optimized for 265 
obtaining the maximum abundance of precursor and product ions. In the full scan mode, 6BIO 266 
exhibited two isotopic peaks: 353.9872 and 355.9852 (negative mode) vs 356.0027 and 357.0015 267 
(positive mode). Both isotopes were taken into consideration to generated MS/MS spectra as 268 
summarized in table 1. 269 
Linear Ion Trap full scan and MS/MS spectra of 6BIO were further acquired using the same 270 
conditions utilized for Orbitrap acquisition. For MS/MS experiments, the collision energy voltage 271 
for the effective fragmentation of the selected precursor ions of 6BIO was optimized over the range 272 
of 5-35% with a 2% step, and it was shown that 17% provided optimum fragmentation of 6BIO in 273 
negative mode and 19% in positive mode (Figure 2). 274 
In both Orbitrap and Linear Ion Trap acquisitions, negative mode provided greater S/N ratio as 275 
compared to positive mode. However, the Linear Ion Trap rather than the Orbitrap provided more 276 
stable measurement since CV % values obtained employing Orbitrap analysis were in general > 277 
35% and usually 10-fold higher than those in the case of Linear Ion Trap. Furthermore, the CV % 278 
and RE % remained the same whether selecting either isotope ion or both. Considering all the 279 
above, the Ion Trap operation at negative mode was selected for the analyses with a CID of 17% 280 
for the selected 354 ion of 6BIO. The IS MS/MS spectrum was acquired using a 35% CID as 281 
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previously reported (40). Product ions of 6BIO and IS after fragmentation with the Linear Ion trap 282 
are shown in figure 3. 283 
The chromatographic conditions were optimized for the rapid and efficient separation of 6BIO and 284 
IS from plasma components. For this reason, a 5 cm length C18 silica column was chosen with 285 
acetonitrile as the organic mobile phase over methanol as this combination gave the best results in 286 
terms of peak shape (width, symmetry, sharpness) and accelerate the analysis time. Further 287 
optimization was achieved by adding 0.1% acetic acid in the aqueous mobile phase enhancing 288 
therefore the ionization efficiency in comparison to various percentages of formic acid. Under the 289 
optimized chromatographic conditions 6BIO was eluted at 3.08 min. and afromorsin (IS) at 2.52 290 
min (Figure 4). 291 
3.2. Sample preparation 292 
Numerous methods were evaluated for the sample preparation procedure. Specifically, (i) protein 293 
precipitation with cold mixture of acetonitrile/methanol at various ratios (1/9, v/v), (3/7, v/v), (1/1, 294 
v/v), (7/3, v/v), and (9/1, v/v); (ii) liquid-liquid extraction, and (iii) SPE extraction. Amongst all, 295 
protein precipitation with cold acetonitrile/methanol (9:1, v/v) was chosen as it presented the 296 
highest recovery factor, the least matrix effect and was the less time consuming presenting also 297 
adequate sensitivity for the PK study of 6-BIO concentration after its administration to mice. 298 
3.3. Choice of the IS 299 
Afromorsin was selected as the IS mainly due to the fact that it is a readily available, inexpensive, 300 
not harmful and stable substance that could be ionized in the negative ionization mode. Moreover, 301 
afromorsin was eluted before 6BIO and was well separated from 6BIO without interference from 302 
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endogenous compounds in rat plasma, whereas its chromatographic characteristics were 303 
appropriate. 304 
3.4. Method validation 305 
3.4.1. Selectivity 306 
 307 
The selectivity of our method refers to its ability to select and determine particular 6BIO and IS in 308 
plasma without interfering with the other metabolites. Therefore five plasma sample at the LLOQ 309 
were analyzed. The selectivity precision (CV %) was 9.62%, and the accuracy (RE %) was 1.14% 310 
(Table 2). Since the precision was below 20%, and the accuracy was within ±20% at the LLOQ, 311 
this analytical method for the quantification of 6BIO in rat plasma was shown to be selective. 312 
3.4.2. Specificity 313 
 314 
The specificity of the proposed analytical methodology was assessed by the analysis of six blank 315 
drug-free plasma samples. Analysis of these blank samples under the same conditions revealed no 316 
interference peaks from endogenous plasma components at the retention times of 6BIO and IS; the 317 
peak areas measured in the blank plasma sample were equal to 0.00% and, hence, less than 20.0% 318 
of the LLOQ average peak area, indicating that this analytical method is specific for 6BIO and 319 
suitable for bioanalysis. The representative chromatograms of blank rat plasma and plasma spiked 320 
with 6BIO at LLOQ and ULOQ and IS are shown in Figure 4. 321 
3.4.3. Calibration range, calibration model, and LLOQ  322 
 323 
Having no idea of the concentration of samples to be analyzed, and in order to avoid working with 324 
either a very large or a very narrow calibration curve, we firstly performed a preliminary 325 
calibration curve of 6BIO alone over the range 1 – 5000 ng/mL along with representative plasma 326 
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samples of the PK study. After analysis of the data, our concentration range was narrowed to 5 – 327 
200 ng/mL; final calibration curves were constructed by plotting the peak area ratios of 6BIO to 328 
IS of plasma and calibration standards versus nominal concentrations of 6BIO. The calibration 329 
model was selected based on the analysis of the data by linear and non-linear regression as well as 330 
with and without weighting. The curve fitting was based on the simplest model that exhibited the 331 
highest correlation coefficient along with the lowest RE% on the back-calculated values. 332 
Calibration curves of five different lots of plasma calibration standards were constructed (Table 333 
3).  334 
The best fit and least square residuals for the calibration curves were achieved employing a 335 
quadratic model with 1/x weighting factor. The correlation coefficient (r2) of the calibration curve 336 
was > 0.998, indicating good correlation. The back calculated values obtained are within the 337 
proposed 15% margin of the nominal concentrations indicating the adequacy of the proposed 338 
model. The LLOQ of 6BIO with the proposed method was determined to be 5 ng/mL fulfilling the 339 
specification  that RE % and CV % should fall into the 20% margin and the S/N the analyte should 340 
be at least 5 (at least 5 times the signal of a blank sample). 341 
In order to clarify if the calibration curves were the same an extra sum of squares F-test has been 342 
carried out. The results show that the calibration curves obtained do not differ statistically and 343 
therefore each one could be substituted either by one other in the set or could be described by one 344 
common curve. The consensus curve can be expressed by the following equation:  345 
Y=0.00015(±0.00014)*X2+0.97(±0.02)*X+0.20(±0.39) 346 
The numbers in parentheses denote the standard error. The back calculated values calculated by 347 
the equation exhibit RE % values less than 15% for all points whereas the coefficient of the 348 
determination is better than 0.998.  349 
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3.4.4. Accuracy and precision 350 
 351 
The intra- and inter-day precision and accuracy were evaluated at the three QC levels as well as at 352 
the LLOQ and ULOQ levels (Table 4). As shown in Table 4 the intra-day precision does not exceed 353 
10.11 % whereas the inter-day was better than 9.62 % in every case. The RE %, indicating the 354 
accuracy of the method does not exceed 13.29%. Therefore, this bio-analytical method proved to 355 
be precise and accurate. 356 
3.4.5. Recovery and matrix effect 357 
 358 
In order to evaluate the recovery of 6BIO, twenty-five blank mouse plasma samples from five 359 
different animals were processed without addition of 6BIO and concomitantly they were spiked 360 
with 6BIO at the LLOQ, ULOQ, and QCs concentration levels (post spiked samples). The 361 
responses obtained represented the 100% recovery reference. The extraction recovery was 362 
calculated by dividing the peak area ratio of the post-spiked samples by the corresponding peak 363 
area ratio of the pre-spiked samples (spiked before protein precipitation). Similarly, the potential 364 
ion suppression or enhancement due to mouse plasma components (matrix effect) was evaluated 365 
by dividing the peak area ratio of the post-spiked plasma samples by the corresponding peak area 366 
ratio of working standard solutions diluted in MeOH:H2O (1/1, v/v). The extraction recovery of 367 
6BIO was between 97.1 and 124.4 % across the entire range (5 - 200 ng/mL), while the matrix 368 
effect was between 73.8 and 85 % for 6BIO (Table 5). 369 
3.4.6. Carry-over 370 
 371 
The impact of the carry-over on blank mouse samples following the highest calibration sample 372 
was assessed for both 6BIO and IS. The average carry-over was 1 % (below 20%) for 6BIO and 373 
0.04 % (below 5%) for the IS, indicating that the carry-over has no impact on the results. 374 
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3.4.7. Stability 375 
 376 
No significant degradation have been observed under the stress condition imposed as described 377 
during the stability study (Table 6). Therefore, no special precautions are advised besides the ones 378 
described. 379 
 380 
3.4.8. Robustness 381 
 382 
Upon variation of the flow rate, the column temperature, and the percentage of acetic acid in 383 
aqueous phase, the retention time shift of 6BIO and IS remained statistically not significant at the 384 
95% level using ANOVA.  385 
3.5 Pharmacokinetic Study  386 
 387 
This validated method was successively applied to a pharmacokinetic study of 6BIO in mice. The 388 
mean plasma concentration – time curve after a single oral administration of 6BIO at 50 mg/kg 389 
BW is shown in Figure 5.  390 
The main pharmacokinetic parameters of 6BIO calculated using PKsolver software are 391 
summarized in Table 7. After administration of 6BIO, the mean maximum concentration (Cmax) 392 
was 118.2 ± 58.7 ng/mL, and the area under the concentration-time curve (AUC0-Inf) was 155.32 393 
± 34.99 ng*h/mL. The plasma concentration of 6BIO decreased rapidly and was eliminated from 394 
the plasma with a half-life time (t1/2) of 0.72 ± 0.09 hours.  395 
This study with an oral administration of 50 mg/kg BW validated the bioanalytical method 396 
developed and could be suitable to detect 6BIO levels in mouse plasma. Overall, low 397 
bioavailability and  rapid decrease of 6BIO concentrations in plasma is observed. The low 398 
bioavailability could be attributed to the low solubility of 6BIO (sparingly soluble in aqueous 399 
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buffres, 0.3 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2)). The rapid decline of plasma 400 
concentrations might result from rapid distributions to other tissues. In future PK studies, we will 401 
investigate the distribution of 6BIO to other tissues after oral administration and the PK after  402 
intravenous injection can improve the plasma bioavailability of 6BIO.   403 
4. Conclusion 404 
The described UHPLC-ESI-MS/MS analytical methodology enables the rapid and selective 405 
determination of 6BIO in mouse plasma. The developed method is robust and presents high 406 
sensitivity, accuracy, precision, recovery, and stability. A small amount of plasma is required using 407 
this method (45 μL), making it applicable for many bio-analytical studies which generally present 408 
limited amount of sample. A time-saving one-step protein precipitation for sample pretreatment, 409 
combined to the rapid analysis time (4.4 min) render this method readily applicable in a further 410 
clinical study, comprising a large amount of samples and need for high-throughput method. The 411 
method was therefore applied to a preliminary pharmacokinetic study of 6BIO after oral 412 
administration of 50 mg/kg in mice. The pharmacokinetic profile of 6BIO was characterized for 413 
the first time and this showed a low bio-availability and a rapid elimination of 6BIO from the 414 
systemic circulation in mice. 415 
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List of figures 513 
Figure 1: Chemical structures of 6BIO and Afrormosin. 514 
Figure 2: Gradient CID for the fragmentation of 6BIO at Ion trap (A) and Orbitrap (B). 515 
Figure 3: Ion trap product ions of 6BIO (left) and IS (right) applying CID of 17% and 35% 516 
successively. 517 
Figure 4: Representative segmented MRM chromatograms of: (A) blank mouse plasma sample, 518 
(B) LLOQ mouse plasma spiked with 6BIO (5 ng/mL) and IS (50 ng/mL), (C) LLOQ mouse 519 
plasma spiked with 6BIO (200 ng/mL) and IS (50 ng/mL), and (D) plasma sample collected 5 min 520 
after oral administration of 6BIO (50 mg/kg) to mice.  521 
Figure 5: Mean plasma concentration time profile of 6BIO in mice (n = 3) following oral 522 
administration (50 mg/kg BW). For representative reason, time points have been constrained up to 523 
6h. 524 
 525 
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Table 1: High resolution precursor and product ions of 6BIO in positive and negative ESI-Orbitrap 527 
Precursor ions CID Product ions  
Negative 353.9872 17 323.9893 
355.9852 17 325.9872 
Positive  356.0027 20 326.0045 
357.0015 20 328.0035 
 528 
  529 
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Table 2: Selectivity test at the LLOQ for 6BIO (n = 5) 530 
 531 
  532 




Mean SD RE % CV % 
1 1 5 4.893 5.1 0.49 1.14 9.62 
2 5 4.491 
2 1 5 4.961 
2 5 4.556 
3 1 5 5.882 
2 5 5.873 
4 1 5 4.794 
2 5 4.780 
5 1 5 5.210 
2 5 5.130 
SD:  standard deviation 
RE %: deviation of mean from the nominal value 
CV %: coefficient of variation 
28 
 
Table 3: Calibrators and calibration curve parameters 533 
Run  Nominal values (ng/mL) r2 
5 10 25 50 75 100 125 150 200 
1 4.9 9.2 24.4 51.0 71.7 105.3 122.9 151.2 207.7 0.998 
4.5 9.8 24.4 52.2 70.6 104.2 124.0 146.0 212.6 
2 4.6 9.4 22.6 49.7 78.5 101.6 125.0 150.2 220.7 0.999 
4.9 10.6 23.0 48.5 77.2 98.0 129.1 147.8 202.7 
3 4.3 12.1 25.2 49.9 84.5 99.6 116.9 137.1 206.6 0.992 
4.3 10.0 24.1 53.6 84.4 97.7 115.0 135.6 219.4 
4 4.7 9.9 26.3 52.1 80.6 99.1 118.7 129.9 204.8 0.998 
6.1 10.5 25.0 48.8 76.0 95.3 123.3 123.1 200.3 
5 5.4 10.4 23.7 52.3 84.7 92.3 120.4 146.5 201.8 0.997 
5.1 9.7 25.4 51.9 80.7 93.8 119.1 148.2 209.0 
Mean 4.9 10.1 24.4 51.0 78.9 98.7 121.4 141.6 208.6  
SD 0.56 0.83 1.13 1.68 5.09 4.25 4.21 9.60 7.07 
RE % -2.32 1.44 -2.39 1.98 5.19 -1.32 -2.85 -5.62 4.28 
CV % 11.47 8.14 4.61 3.29 6.45 4.31 3.46 6.78 3.39 
 534 
Run 1:   Y1 = 0.0025 + 0.011*X - 1.33e-005*X^2       r2 = 0.998  535 
Run 2:   Y2 = -0.0052 + 0.013*X - 8.22e-006*X^2        r2 = 0.999  536 
Run 3:   Y3 = 0.0002 + 0.008*X - 2.04e-006*X^2     r2 = 0.992  537 
Run 4:   Y4 = 0.0123 + 0.007*X - 1.00e-006*X^2           r2 = 0.998  538 
Run 5:   Y5 = 0.0002 + 0.007*X + 2.68e-007*X^2     r2 = 0.997  539 
  540 
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Table 4: Within- and between-series precision (CV %), and accuracy (expressed as RE %) of 541 
LLOQ, ULOQ and QC samples 542 
Level  Found 
Day1 Day 2 Day 3  Overall 
n =5 n = 5 Run 1 (n = 5) Run 2 (n = 5) Run 3 (n = 5) n = 25 
LLOQ (5 ng/mL) 
Mean 5.1 5.1  5.0  4.9 5.0  5.1 
SD 0.49 0.40  0.35  0.14  0.21  0.06 
RE % 1.14 2.51  0.77  2.00  1.00  1.39 
CV % 9.62 7.79  7.02  2.89  4.29  1.14 
LQC (7.5 ng/mL) 
Mean 7.6 7.8 7.4 6.5  8.4  7.3 
SD 0.59 0.29 0.74 0.47  0.85  0.57 
RE % 1.83 4.10 1.93 13.29  12.06  2.33 
CV % 7.70 3.69 10.11 7.24  10.08  7.83 
MQC (40 ng/mL) 
Mean 43.1 39.1 44.2 44.5 42.6  42.7 
SD 1.89 1.37 1.44 1.50 2.42  2.16 
RE % 7.83 2.23 10.47 11.31 6.46  6.75 
CV % 4.39 3.51 3.27 3.37 5.69  5.05 
HQC (175 ng/mL) 
Mean 185.3 175.1 185.2 186.5  181.8  183.0 
SD 5.77 8.67 12.94 12.74  5.32  5.32 
RE % 5.86 0.05 5.85 6.54  3.86  4.59 
CV % 3.12 4.95 6.99 6.83  2.92  2.90 
ULOQ (200 ng/mL) 
Mean 200.7 199.8  194.9  206.9  195.0  200.3 
SD 15.44 9.53  0.74  7.85  2.83  0.64 
RE % 0.35 0.09  2.6  3.43  2.50  0.13 
CV % 7.69 4.77  0.38  3.79  1.45  0.32 
 543 
  544 
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Table 5: Recovery of 6BIO in mouse plasma and matrix effect (n = 5) 545 
Level ng/mL Matrix effect (%) SD RE % CV % Recovery (%) SD RE % CV % 
LLOQ  5 73.8 9.36 26.25 12.69 98.5 3.42 1.54 3.48 
LQC 7.5 83.6 13.28 16.45 15.89 109.0 12.66 9.02 11.6 
MQC 40 85.0 6.53 15.00 7.68 97.1 4.80 2.86 4.94 
HQC 175 82.8 3.57 17.25 4.31 94.6 7.65 5.41 8.08 
ULOQ 200 79.5 2.57 20.50 3.23 124.4 2.83 24.36 2.28 
 546 
  547 
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LLOQ 5  5.1 10.00 9.80  4.95 5.00 6.06  5.12 12.00 5.86  5.03 3.00 9.94 
LQC 7.5 7.7 2.67 9.09  6.9 8.00 10.14  7.40 1.33 13.51  7.55 0.67 10.60 
MQC 40 42.5 6.25 5.53  44.0 10.0 8.07  43.5 8.75 10.46  40.50 1.25 14.57 
HQC 175 180.5 3.14 5.82  173.5 0.86 3.07  173.5 0.86 4.32  170.5 2.57 5.87 
ULOQ 200 201.1 0.55 3.73  205.5 2.75 3.16  199.5 0.25 3.76  195.0 2.50 3.85 
 549 
  550 
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Table 7: Non-compartmental pharmacokinetic parameters of 6BIO in plasma after a single oral 551 
dose of 50 mg/kg BW to mice (n = 3). 552 
Parameter Unit Mean values SD 
Tmax h 0.50 0.0 
Cmax ng/mL 118.2 58.7 
Elimination rate 
constant (Ke) 
1/h 0.97 0.12 
Terminal elimination 
half-life (t1/2) 
h 0.72 0.09 
AUC 0-t ng/mL*h 155.3 35.0 
AUC 0-inf ng/mL*h 157.6 36.2 
MRT 0-inf h 0.98 0.16 
Vz/F (mg/kg)/(ng/mL) 0.35 0.13 
Cl/F (mg/kg)/(ng/mL)/h 0.33 0.09 
 553 
 554 
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